Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials

Emerging Immunotherapies in the Treatment of Brain Metastases

Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade

Blockade of CTLA-4 increases anti-tumor response inducing potential of dendritic cell vaccine

Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma

Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine

Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization

Past, Current, and Future of Immunotherapies for Prostate Cancer